2021 AABB Annual Meeting On-Demand

Oct 17, 2021 ‐ Oct 19, 2021


Access to the 2021 AABB Annual Meeting On-Demand sessions expires on December 31, 2023. Each session includes the on-demand recording and a downloadable MP3 audio file. Closed captioning in Spanish and English also available for most sessions. Some speaker handouts may be available, but in general, presentation handouts are not available/included.



Sessions

AM21-84: Identifying Current and Future Best Practices in Perinatal Patient Testing and Care

Oct 19, 2021 9:00pm ‐ Oct 19, 2021 10:00pm

Credits: None available.

The transfusion service plays a critical role in the management of perinatal patients. This interactive session will engage the audience and speakers in an active discussion on approaches for testing and management of this patient population. Topics presented are those identified as controversial or for which there is no unified approach and include: 

  • The timing and frequency of type and screens during pregnancy, and the need for type and screen with crossmatch at delivery.
  • The indications to perform molecular tests i.e., maternal RHD genotyping to distinguish weak D from partial D and fetal RHD genotyping using cell-free DNA to make decisions regarding the need for monitoring and Rh immune globulin administration.
  • Guidance about antibody critical titer thresholds and the appropriate management once critical titer is reached.
  • Suggestions regarding which cord blood tests should and should not be performed to diagnose and assess future risk of hemolytic disease of the fetus and newborn.

To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Design a strategy for determining the frequency and interpretation of antibody titers and when referral to a high risk fetomaternal specialist is required.
  • Identify which molecular tests are available and when they may be beneficial in the management of obstetric patients at risk for hemolytic disease of the fetus and newborn.
  • Judge when and which tests performed on cord blood samples may benefit patient outcomes.
  • Identify gaps where protocols and guidelines for the management of obstetrics patients are not available.
Moderator(s):
  • Dr. Mark K. Fung, MD, PhD, Director of Clinical Laboratories, University of Vermont Medical Center
Speaker(s): Disclosures
  • Wen Lu, MD : Nothing to Disclose
  • Lani Lieberman, MD : Nothing to Disclose
  • Mark Fung, MD, PhD : Consultant: Cerus Corporation, Biocogniv; Honoraria: Grifols Corporation
Members: $20.00
Standard: $25.00

AM21-85: A New Look at Two Familiar Topics: Platelet Transfusion Support for Immune Refractory Patients and the ABO COVID-19 Connection (AABB-ASHI Joint Symposium)

Oct 19, 2021 9:00pm ‐ Oct 19, 2021 10:00pm

Credits: None available.

In this session, our first presenter will discuss an unique algorithm for selecting compatible platelets for alloimmune refractory patients. The second presenter will review recent research on ABO antibodies and the differential susceptibility of ABO blood groups to COVID-19.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Describe the current findings regarding ABO and susceptibility to COVID-19 infection.
  • Discuss how knowledge of the complexity of ABO antigens and antibodies may help explain differential susceptibility to COVID 19
  • Compare the platelet donor selection method described in the presentation with the “HLA matching” method for selecting platelet donors for immune refractory patients
Moderator(s): Speaker(s): Disclosures
  • Manish Gandhi, MD : Nothing to Disclose
  • Carol Pancoska, PhD : Nothing to Disclose
  • Lori West, MD, DPhil, FRCPC : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-86: AABB-ISCT Joint Working Group Project Updates

Oct 19, 2021 9:00pm ‐ Oct 19, 2021 10:00pm

Credits: None available.

In 2014, executive leadership at AABB and ISCT agreed to establish a joint working group (WG) for the purpose of identifying issues common to both organizations in the cellular therapy (CT) arena and exploring advocacy issues on which both organizations can collaborate. The WG has been involved in several projects since then. This session will provide updates on two of the current projects executed by two teams of experts recruited through the WG.

Project 1: Considerations for the Establishment of a CT Product Stability Program

The goals of the project are to:

  • educate the community regarding considerations for CT stability programs
  • create reference documents/communication materials to help with the design of a stability program for hematopoietic stem/progenitor cell products

Project 2: Establishment of a GTP interpretative tool that can assist with clarification of Human Cells, Tissues and Cellular-Based Products (HCT/Ps) regulations under 21 CFR 1271 and Section 361 of the PHS Act and/or the FD&C Act

The goals of this project are to:

  • educate community regarding interpretation of GTP requirements and how best to prepare for FDA inspections of establishments that manufacture HCT/Ps
  • create a tool providing section-by-section guidance specific to the needs of a CT laboratory to achieve regulatory compliance and preparation for unannounced FDA inspections

To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Moderator & Speaker(s):
  • Lizette Caballero, MLS(ASCP), Senior Laboratory Supervisor , Janssen Pharmaceutical Companies of Johnson & Johnson
Speaker(s):
  • J. Wade Atkins, MS, MT(ASCP) SBB, CQA (ASQ), National Institutes of Health
  • Nadim Mahmud, MD, PhD, University of Illinois College of Medicine
Disclosures
  • J. Wade Atkins, MS, MT(ASCP) SBB, CQA (ASQ) : Nothing to Disclose
  • Nadim Mahmud, MD, PhD : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-91: Solve It! Scenarios in Cellular Therapy

Oct 19, 2021 12:30pm ‐ Oct 19, 2021 2:00pm

Credits: None available.

We all face challenges in our daily work activities within Cellular Therapy: What is the best approach to manage storage space? How to deal with supply and reagents shortages? How to handle the growing number of clinical trials? How to be better prepared for the next disaster? Or how to adjust training and competency programs to accommodate the changing workforce?

The Solve It! Scenarios in Cellular Therapy session offers an interactive and constructive program for Cellular Therapy professionals to share challenges through case scenario presentations. This program permits attendees to select topics of particular interest, rotate through multiple scenario case presentations in small, informal groups, and develop problem solving strategies. Join us for lively interactions and networking with experts in the field of Cellular Therapy and fellow colleagues.

Closed captioning in English and Spanish is not available for this session.

Learning Objectives:
  • Discuss creative solutions to manage common technical, clinical, and administrative challenges using case scenario approach.
  • Review regulatory requirements and accreditation standards while developing strategies to resolve mutual hurdles in daily practices.
  • Assemble with cellular therapy colleagues and experts in the field in a congenial and informal atmosphere.
Moderator & Speaker(s): Speaker(s): Disclosures
  • Ronit Slotky, PhD : Nothing to Disclose
  • Federico Rodriguez Quezada, SBB, MLS(ASCP) : Nothing to Disclose
  • Indira Guleria, Ph.D. Diplomate (ABHI) : Nothing to Disclose
  • Wanxing Cui : Nothing to Disclose
  • Matt Wilgo : Full-time/Part-time Employee New England Cryogenic Center
Standard: $30.00
Members: $25.00

AM21-92: AABB Cellular Starting Material Forum

Oct 18, 2021 12:30pm ‐ Oct 18, 2021 2:00pm

Credits: None available.

The AABB Cellular Starting Material (CSM) Forum connects cell collection organizations to the biotherapies ecosystem. CSM is used for a variety of novel biotherapies including cellular therapy, gene and cell therapy, and regenerative medicines. The CSM Forum explores standards development, industry, and regulatory perspectives as well as strengthening the capacity for cell collection organizations to meet current and future demand for qualification to collect CSM.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Describe the various forms of cellular starting material (CSM) in the biotherapies sector
  • Recognize the connection between cell collection organizations as integral to the biotherapies ecosystem
  • Explain current and future tools and resources available to AABB members
Moderator & Speaker(s): Moderator(s): Speaker(s): Disclosures
  • Linda Barnes, DrPH, MHA, RAC : Employee: X-Cell Systems
  • Katie Zander : Employee: Kite Pharma
  • Christopher Bocquet : Nothing to Disclose
  • Judy Arcidiacono : Nothing to Disclose
  • Peter Holman : Nothing to Disclose
  • Tracey Hlucky : Employee: Kite Pharma
  • Jean Stanton : Nothing to Disclose
  • Eduardo Nunes, MPP, CAE : Nothing to Disclose
Standard: $30.00
Members: $25.00